Biotechnology News

CAMBRIDGE, Mass., April 20, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...

BERKELEY, CA--(Marketwire - Apr 20, 2011) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the start of dosing in the first human clinical trial in its lupus program. Initiation of...

EDMONTON, ALBERTA--(Marketwire - April 20, 2011) -Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or "the Company") today released financial and operating results for the fiscal year ended December 31, 2010....

WARRINGTON, Pa., April 20, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), will be presenting new data supporting its KL4 surfactant aerosolization program at the Pediatric...

God volymutveckling och en ökning av intäkterna med 10% trots negativa valutaeffekter och fullt genomslag av tidigare prissänkningar. Kennet Rooth, VD:" Vi hade en god volymutveckling under kvartalet...

Good volume growth and a 10% increase in revenues despite negative currency effects and full impact of earlier price reductions Kennet Rooth, CEO: "We had a good volume growth for ReFacto® during the...

Not for release, publication or distribution in the United States, Canada, Australia or Japan This announcement does not constitute an offer to sell or the solicitation of an offer to buy the...

Ikke til offentliggørelse eller distribution i USA, Canada, Australien eller Japan. Denne meddelelse er ikke et tilbud om køb eller salg af værdipapirer i Bavarian Nordic A/S ("Værdipapirer") i USA...

In order to read Genmab’s Articles of Association please see the attached file. Contact: Helle Husted, Vice President, Investor Relations T: +45 33 44 77 30 M: +45 25 27 47 13 E:...

Se venligst vedhæftede selskabsvedtægter for Genmab A/S. Kontakt: Helle Husted, Vice President, Investor Relations T: +45 33 44 77 30 M: +45 25 27 47 13 E:...